

LETTER TO THE EDITOR

Genetic diversity of newly diagnosed follicular lymphoma

Blood Cancer Journal (2014) 4, e256; doi:10.1038/bcj.2014.80; published online 31 October 2014

Follicular lymphoma (FL) is the second most common form of non-Hodgkin lymphoma (NHL) and often follows an indolent disease course with slow progression.^{1,2} However, patients may develop resistant disease; in addition, transformation to a more aggressive subtype of lymphoma occurs at a rate of 2–3% per year.^{3–5,6} FL arises from germinal center B cells and the most common molecular defect is t(14;18)(q32;q21) in 85–90% of the cases, which results in the *IGH-BCL2* fusion gene and the overexpression of the anti-apoptotic oncogene *BCL2*.⁷ However, the t(14;18) is also observed in healthy individuals and FL patients who are in long-term remission² suggesting the existence of additional genomic alternations that impact disease course. Recently, massive parallel exome or whole genome sequencing of FL tumors and follow-up validation studies have discovered that point mutations in genes involved in epigenetic regulation and chromatin modification, including *MLL2*, *EZH2*, *CREBBP*, *EP300* and *MEF2B*, dominate the FL landscape.^{8–12} Mutations in *JAK-STAT* pathway genes and B-cell receptor (*BCR*)/*NF-κB* signaling genes have also been identified, but with lower frequencies.¹¹


Whole genome and exome sequencing studies to date have primarily focused on identification of small site mutations that are recurrent in FL tumorigenesis^{8,9} or involved in tumor clonal evolution.^{11,13} A comprehensive genomic and transcriptomic survey of multiple mutation types of different sizes in FL patients with detailed clinical annotations and long-term follow-up has not been accomplished. To gain insight into genetic biomarkers that may predict clinical features, we performed exome and whole genome mate-pair sequencing of fresh frozen tumor and paired peripheral blood DNAs, and transcriptome sequencing of tumor RNAs, from eight FL patients. This comprehensive genomic and transcriptomic profiling enables the detection of not only small site mutations (single nucleotide variants or SNVs; and small insertions and deletions or INDELs), but also large structural mutations such as copy number variants (CNVs), translocations and inversions in FL tumors. The patients

sequenced were either below the median age of FL onset ($n = 7$, median 54.5 years old) or had a family history of FL ($n = 1$) (Table 1). All samples were from the patient's initial diagnosis. These patients were clinically diverse, and included patients who had Grade 1 or 2 disease ($n = 4$), classified as 'indolent'; and patients with Grade 3a disease ($n = 2$) or who subsequently had pathologic transformation ($n = 2$), classified as 'aggressive' (Table 1). An overview of all SNVs, small INDELs, large SVs and CNVs in individual patients is illustrated in Figures 1a–c, which highlights the genetic heterogeneity of these eight newly diagnosed FL. Our analysis of SNVs and INDELs revealed mutations in previously reported genes including *MLL2*, *CREBBP*, *TNFRSF14* and histone cluster genes (*HIST1H2AM* and *HIST1H2BD*) (Figure 1c and Supplementary File S1), although the mutation frequencies of some genes are lower in our samples. For example, *MLL2* and *CREBBP* were reported to be mutated in >80% and >60% of the FL cases^{9,11,12} whereas we detected *MLL2* mutations in three out of eight cases (38%) and *CREBBP* mutations in two out of eight (25%) cases. In addition to the previously reported genes, we also identified novel recurrent mutations in cysteine-rich PAK1 inhibitor (*CRIPAK*) in two out of eight tumors. In a secondary analysis performed by Sanger sequencing in a second cohort of FL and diffuse large B-cell lymphoma (DLBCL) tumors, we identified *CRIPAK* mutations in 55% of FL (11 out of 20) and 38.7% of DLBCL (12 out of 31) tumors (Supplementary File S6, Figure A). Bioinformatics analysis shows that the coding region of *CRIPAK* is highly enriched with the protein functional domain, post-SET, which is found in histone lysine methyltransferases genes including *MLL2* and *EZH2* that are known to be important in lymphomagenesis. Interestingly, *CRIPAK* is part of the same regulatory network of 31 genes including previously identified lymphoma genes such as *MLL2*, *EZH2*, *CREBBP*, *EP300*, *TP53*, *MYC*, *STAT6* and *BCL2*, according to the shortest path algorithm by MetaCore (Philadelphia, Pennsylvania) (Supplementary File S4, Supplementary File S6 Figure A). We showed that the connectivity between the 31 genes in this network is highly significant with an empirical *P*-value of 0 based on 10 000 simulations of calculating average pair-wise shortest distances from randomly chosen proteins from the protein-protein-interaction database (Supplementary File S6 Figure A).

Table 1. Patient clinical characteristics

Patient	Sex	Age	Grade	Stage	FLIPI	Initial treatment	Outcome
<i>Indolent FL grade I/II</i>							
1	F	56	1	IV	1	Observation	Alive and treatment-free at 100 months
2	M	39	2	III	2	Rituximab (RESORT)	Alive and progression-free at 79 months
3	M	56	2	III	1	Observation	Progression at 8 months, alive at 63 months
4	M	55	2	II	0	R-CHOP	Progression at 70 months, alive at 78 months
<i>Aggressive FL grade III and transformed cases</i>							
5	F	52	1	IV	4	R-CVP	Progression at 16 months, transformation at 49 months, alive at 142 months
6	M	66	2	III	3	CVP	Transformation at 1 month, alive at 71 months
7	M	41	3A	III	1	Lenalidoimide+R-CHOP trial	Alive and progression-free at 46 months
8	M	54	3A	IV	3	R-CHOP	Progression at 35 months, alive at 77 months

Abbreviations: CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone; CVP, cyclophosphamide, vincristin, prednisone; F, female; M, male; R, rituximab.






Figure 1. The mutation landscape of eight FL tumors. (a) Circos plots of tumor-specific structural variants (SVs) identified from whole genome mate-pair sequencing data and somatic copy number variants (CNV) detected in the exome sequencing data. The case number of each patient is indicated in the center of each Circos plot. SVs are displayed either in blue (with inversion) or green (without inversion) lines connecting the two break points within the same chromosome or across two different chromosomes. The thickness of the lines correlate with the number discordant read pairs supporting the SV. The common t(14;18) translocations are labelled. The two outer rings of the Circos plots are the display of the CNVs observed in mate-pair and exome sequencing data, respectively. The green outward dots and lines are amplifications and the red inward dots and lines are deletions. Note that only the CNVs supported by both mate-pair and exome sequencing data were discussed in this manuscript. (b) Number of genes per tumor located within somatic CNV regions from the exome-sequencing data (upper panel); number of genes with somatic point mutations per tumor (including SNVs and small INDELS) (middle panel); and number of genes involved in large SVs per tumor (lower panel) are plotted. (c) SNV and small INDEL mutation status of previously reported genes and CRIPAK; the observed SVs; as well as several clinical factors of eight FL tumors.

Recurrent structural variants identified in the FL tumors included the well-known *IGH-BCL2* translocation or t(14;18), in six out of eight cases (75%) and chromosome 1q amplifications in four out of eight (50%) tumors (Figure 1a, Supplementary Files S3 and S7). Other nonrecurrent large CNVs involving entire chromosomes or at arm levels, as well as other inter- and intra-chromosomal structural variants were also detected in individual tumors (Figure 1a, Supplementary Files S3 and S7). In addition, we identified six fusion transcripts from the transcriptome sequencing data in three out of eight cases (38%) (Supplementary File S5, Supplementary File S6 Figure B). Copy number alteration gains in 1q21-q31 have been reported in ~50% of FL¹⁴ and ~20% of DLBCL¹⁵ using nonsequencing based technologies including array comparative genomic hybridization and fluorescence *in situ* hybridization. The functional significance of the CNV gains in this region is still unknown. However, the prominent amplification of the region may indicate a potential role for this variant in lymphomagenesis.

Although our sample size was small, we found that SNVs and INDELS in *MLL2*, *CREBBP*, *TNFRSF14*, *CRIPAK* and histone cluster genes, as well as t(14;18), did not distinguish the indolent tumors from the aggressive tumors. However, gains in chr1q (4/4, 100%) and the presence of RNA fusion transcripts (3/4, 75%) were specific to aggressive tumors and were not detected in any of the indolent tumors. In addition, we found that the grade 3A tumors and the subsequently transformed tumors had higher numbers of genes with point mutations (SNVs and short INDELS) (40 ± 7.6 vs 26 ± 2.6 ; aggressive vs indolent), higher numbers of genes impacted by copy number alterations (1060 ± 263.7 vs 233 ± 133.9 ; aggressive vs indolent) and higher numbers of large SVs (24 ± 10 vs 6 ± 1.6 ; aggressive vs indolent) (Figure 1b). Taken together, our comprehensive analysis of eight FL tumors reveals genetic diversity among newly diagnosed FL patients, identifies novel and recurrent mutations in *CRIPAK*, and finds that high tumor complexity and DNA instability may be indicators of more aggressive disease.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank the Mayo Clinic Medical Genome Facility for performing library constructions and sequencing of all RNA and DNA samples. This research is supported by NIH grant P50 CA97274 (J Cerhan and A Novak) and the Predolin Foundation.

YW Asmann¹, MJ Maurer², C Wang², V Sarangi², SM Ansell³,
AL Feldman⁴, GS Nowakowski³, M Manske³, T Price-Troska³,
Z-Z Yang³, SL Slager², TM Habermann³, JR Cerhan⁵ and AJ Novak²
¹Department of Health Sciences Research, Mayo Clinic,
Jacksonville, FL, USA;

²Division of Biomedical Statistics and Informatics, Mayo Clinic,
Rochester, MN, USA;

³Division of Hematology, Mayo Clinic, Rochester, MN, USA;

⁴Department of Laboratory Medicine and Pathology, Mayo Clinic,
Rochester, MN, USA and

⁵Division of Epidemiology, Mayo Clinic, Rochester, MN, USA
E-mail: novak.anne@mayo.edu

REFERENCES

- Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. *J Clin Invest* 2012; **122**: 3424–3431.
- Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. *J Clin Oncol* 2010; **28**: 2902–2913.
- Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI *et al.* Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. *J Clin Oncol* 2013; **31**: 3272–3278.
- Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ *et al.* Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. *J Clin Oncol* 2008; **26**: 5165–5169.
- Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C *et al.* Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. *J Clin Oncol* 1997; **15**: 1587–1594.
- Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J *et al.* Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. *J Clin Oncol* 2007; **25**: 2426–2433.
- Conde L, Halperin E, Akers NK, Brown KM, Smedby KE, Rothman N *et al.* Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. *Nat Genet* 2010; **42**: 661–664.
- Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R *et al.* Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nat Genet* 2010; **42**: 181–185.
- Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD *et al.* Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. *Nature* 2011; **476**: 298–303.
- Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V *et al.* Inactivating mutations of acetyltransferase genes in B-cell lymphoma. *Nature* 2011; **471**: 189–195.
- Okosun J, Bodor C, Wang J, Araf S, Yang CY, Pan C *et al.* Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. *Nat Genet* 2013; **46**: 176–181.
- Bodor C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K *et al.* EZH2 mutations are frequent and represent an early event in follicular lymphoma. *Blood* 2013; **122**: 3165–3168.
- Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL *et al.* Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. *Blood* 2013; **121**: 1604–1611.
- Lestou VS, Gascoyne RD, Salski C, Connors JM, Horsman DE. Uncovering novel inter- and intrachromosomal chromosome 1 aberrations in follicular lymphomas by using an innovative multicolor banding technique. *Genes Chromosomes Cancer* 2002; **34**: 201–210.
- Tagawa H, Tsuzuki S, Suzuki R, Karnan S, Ota A, Kameoka Y *et al.* Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases. *Cancer Res* 2004; **64**: 5948–5955.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>

Supplementary Information accompanies this paper on Blood Cancer Journal website (<http://www.nature.com/bcj>)